FMC最後截止日期提醒:業務精湛的投資人法律顧問ROSEN鼓勵FMC Corporation投資人在FMC證券集體訴訟的重要截止日期(1月8日)前尋求法律服務

紐約–(BUSINESS WIRE)–(美國商業資訊)– 原因:全球投資人權益法律事務所Rosen Law Firm提醒在2022年11月2日至2023年10月20日期間(含上述兩個日期,簡稱「集體訴訟期」)購買FMC Corporation (NYSE: FMC)普通股的投資人,申請成為原告代表的截止日期為2024年1月8日。 這意味著什麼:如果您在集體訴訟期內購買了FMC證券,您可能有機會透過勝訴分成安排而獲得賠償,無需支付任何自負費用或開支。 下一步是什麼:如果您想加入FMC集體訴訟,請造訪https://rosenlegal.com/submit-form/?case_id=17626,或撥打免費電話866-767-3653致電Phillip Kim律師,或者寄送電子郵件至pkim@rosenlegal.com或cases@rosenlegal.com,以獲取有關該集體訴訟的資訊。這項集體訴訟已經發起,如果您希望成為原告代表,您必須在2024年1月8日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的代表方。 為什麼選擇ROSEN LAW:我們鼓勵投資人選擇擁

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

LA JOLLA, Calif.–(BUSINESS WIRE)—- $LBPH #Epilepsy–Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is a potentially best-in-clas

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages General Motors Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – GM

NEW YORK–(BUSINESS WIRE)—- $GM #GM–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of General Motors Company (NYSE: GM) between February 2, 2022 and October 26, 2023, both dates inclusive (the “Class Period”), of the February 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased GM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: